Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc. (AQST)

Core Viewpoint - A securities class action lawsuit has been filed against Aquestive Therapeutics, Inc. for allegedly providing misleading information to investors regarding the company's NDA for Anaphylm during the specified class period [1][2]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the District of New Jersey on behalf of all individuals or entities that purchased Aquestive securities between June 16, 2025, and January 8, 2026 [1]. - The complaint alleges that the defendants made overwhelmingly positive statements while concealing material adverse facts about the company's product and its human factors [2]. Group 2: Investor Information - Investors who acquired shares of Aquestive are encouraged to contact the law firm before the lead plaintiff motion deadline on May 4, 2026 [3]. - The lead plaintiff will act on behalf of other class members in directing the litigation [3].